The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
HOME > BUSINESS
BUSINESS
- OncoTherapy Confirms Safety of OCV-C01 for Pancreatic Cancer in PIII Trial
August 17, 2012
- Mizuho Forecasts Sales Increases and Falling Profits in FY2012 for 9 Major Domestic Pharmaceutical Manufacturers
August 17, 2012
- Bonac Confirms Safety of RNAi Agents for Pulmonary Fibrosis in Animal Studies
August 17, 2012
- “Character” Tops List of Traits Doctors Require of MRs: MREAC Survey
August 17, 2012
- Higher Dose of Methotrexate Approved: Pfizer
August 17, 2012
- Teijin Pharma Obtains Approval for Bonalon Jelly
August 16, 2012
- Humira Can Be Used for RA Patients without Treatment History: Abbott, Eisai
August 16, 2012
- Eisai’s US Subsidiary Morphotek Opens New Antibody Production Plant
August 16, 2012
- AZ, Pfizer Enter into Agreement for OTC Nexium, Also Eyeing OTC Versions of Other AZ Products
August 16, 2012
- Additional Indication of Pancreatic Neuroendocrine Tumors Approved for Sutent: Pfizer
August 16, 2012
- Symbicort Approved for COPD: Astellas, AZ
August 16, 2012
- Sosei Discontinues Development of Neuropathic Pain Treatment SD118, Transfers Rights to Beijing Tide of China
August 16, 2012
- MRs Ranks 3rd in Number of Average Annual Holidays at 133 Days: Survey
August 15, 2012
- Otsuka HD to Discuss with FDA this Month Delay in Approving Aripiprazole Injection
August 15, 2012
- Differences in Concurrent-Use Indications for DPP-4 Inhibitors to Be Eliminated through Special Clinical Trials
August 15, 2012
- Seikagaku Wins US Patent Suit over Joint Function Improver
August 15, 2012
- Nichi-Iko to Shift to 2-Headquarters System in Oct.
August 15, 2012
- Otsuka HD’s April-June Pharma Sales Up 2.7% Despite Decline in Abilify Sales
August 15, 2012
- RaQualia Representative Director Nagahisa Steps Down, Mr Tani Appointed New Representative Director
August 15, 2012
- Over 20% of Doctors Report Decline in Meetings with MRs Since Revision of Business Entertainment GLs in April: CareNet Survey
August 13, 2012
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…